Although, this outcome is promising, the similarity in the outcomes of both of these “combination” in vivo experiments where indirect approaches were used to target MCL-1 (i.e. through BH3-only protein upregulation via chemotherapy or genetic deletion), suggests a subpopulation of cells within the tumours remain highly resistant to treatment as the tumours failed to regress. The gene discussed is MCL1; the disease is neoplasm.